Physician profile
Nancy Wilcox
NPI 1003356668
$3,577.81
in general payments reported to CMS, 2019-2025
28 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $543 · 2023: $432 · 2024: $1,051 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,527 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,526.57 |
| Education | $367.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $907.23 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $658.32 | 2021-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $400.32 | 2022-2025 | Erleada, Akeega |
| Merck Sharp & Dohme LLC | $218.45 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Urovant Sciences INC | $205.89 | 2021-2022 | |
| Antares Pharma, INC. | $191.91 | 2022-2025 | Xyosted |
| Olympus America INC. | $146.23 | 2025 | Itind System |
| Abbvie INC. | $93.87 | 2023-2025 | |
| Coloplast Corp | $89.75 | 2024-2025 | |
| Tolmar, INC. | $88.06 | 2024-2025 | Jatenzo, Eligard |
| Ferring Pharmaceuticals INC. | $77.38 | 2024-2025 | Adstiladrin |
| Urogen Pharma, INC. | $56.28 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.38 | 2022-2025 | |
| Tolmar Pharmaceuticals, INC. | $37.21 | 2022 | |
| Endo Pharmaceuticals INC. | $36.93 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $35.97 | 2024 | |
| Medtronic, INC. | $35.67 | 2024 | Interstim |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Teleflex LLC | $33.45 | 2022-2023 | Urolift |
| 180 Medical, INC. | $28.56 | 2023 | Gentlecath |
| Blue Earth Diagnostics | $28.07 | 2025 | Posluma |
| Novartis Pharmaceuticals Corporation | $25.17 | 2022 | |
| Halozyme INC | $24.49 | 2023 | |
| Pfizer INC. | $23.89 | 2025 | |
| Progenics Pharmaceuticals, INC. | $17.54 | 2023 | Pylarify |
| Agiliti Surgical, INC. | $16.86 | 2023 | Sonablate, Soltive |
| Telix Pharmaceuticals | $15.47 | 2023 | Illuccix |
| Clarus Therapeutics INC. | $10.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.